| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 10,280,080 | 11,424,970 | 11,520,500 | 10,666,100 | 9,466,400 |
| Sales Growth | -10.02% | -0.83% | +8.01% | +12.67% | -8.87% |
| Net Income | 2,340,610 | 851,670 | 2,713,320 | 1,927,270 | 2,045,430 |
| Net Income Growth | +174.83% | -68.61% | +40.79% | -5.78% | +265.81% |
Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
Fiscal Year End Date: 12/31